In 2023, Paul Lonergan faced a prolonged sore throat mystery, leading to the discovery of a sizable tumor at the base of his tongue after a series of medical consultations in Toronto. Lonergan, a 68-year-old, embarked on a challenging journey involving seven weeks of radiation and chemotherapy, which landed him in the intensive care unit multiple times. To confirm the eradication of his tumor, Lonergan underwent a “liquid biopsy,” a novel technique utilizing blood tests to identify traces of tumor DNA not visible through conventional scans or exams. Surprisingly, the test revealed lingering tumor fragments in his bloodstream, suggesting a potential resurgence of his successfully treated tongue cancer.
Subsequently, Lonergan received experimental immunotherapy and subsequent liquid biopsies confirmed his cancer-free status. Despite its promising implications, access to this innovative cancer monitoring method remains limited in Canada, mainly confined to clinical trials or private clinics. Dr. Ramy Saleh, a cancer researcher and medical oncologist at McGill University Health Centre, emphasized the groundbreaking potential of liquid biopsies in revolutionizing disease recurrence surveillance.
A Toronto-based team has initiated an extensive long-term research initiative to integrate this evolving technology into standard patient care. The project, named SHERLOCK, spearheaded by scientists from the University Health Network (UHN) in Toronto, aims to provide liquid biopsies to over 7,000 cancer survivors who have undergone traditional treatments over the next five years. Dr. Lillian Siu, the lead of the study, emphasized the project’s focus on early detection of circulating tumor DNA, potentially indicating cancer resurgence.
Liquid biopsies have emerged as a decade-old technology, evolving from requiring large fluid samples to the current ultra-sensitive methods capable of detecting minute DNA molecules in blood. Ongoing research indicates the potential of liquid biopsies in detecting residual disease post-surgery and improving survival rates for various cancers. While still in its early stages, the technology is gradually gaining recognition in healthcare settings, with some hospitals already utilizing it for diagnostic purposes.
Despite the growing interest in liquid biopsies, ethical considerations and the reliability of these tests pose significant challenges. The technology’s imperfections, including false positives and negatives, underscore the need for continuous monitoring and further research to optimize its utility across different types of cancer. The cost implications of routine liquid biopsies remain a hurdle, with efforts underway to demonstrate their cost-effectiveness and clinical benefits.
Dr. Saleh remains optimistic about the transformative impact of liquid biopsies on cancer care, envisioning a future where these tests become routine practice, benefiting a wider patient population. As ongoing trials like SHERLOCK progress, the hope is to provide substantial evidence supporting the widespread adoption of liquid biopsies, ultimately reshaping cancer management strategies globally.